Follicular lymphoma

22 trials 10 recruiting MedDRA PT
22 Registered trials
10 Recruiting
17 Unique sponsors
28 Unique IMPs
15 Commercial trials
Drug classes (ATC)
— ATC code not specified 12
H Endocrinology (ATC H) 2
L Oncology (ATC L) 10
R Respiratory (ATC R) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 7 substances
BTK inhibitor 3 substances
Antibody-drug conjugate (ADC) 2 substances
IMiD 2 substances
Monoclonal antibody (tumor, humanized) 2 substances
Corticosteroid 2 substances
CAR-T cell therapy 2 substances
Monoclonal antibody (rat) 2 substances
Alkylating agent 1 substance
Anthracycline 1 substance
Monoclonal antibody 1 substance
Monoclonal antibody (chimeric) 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Vinca alkaloid 1 substance
Phase III: 6 Phase II: 9 Phase I/II: 1 Phase IV: 1 Phase I: 2 Phase I (Other): 2 Phase I (First in Human): 1

Filter these 22 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 22 trials

Phase III

6 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    BENDAMUSTINE HYDROCHLORIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN HYDROCHLORIDE; EPCORITAMAB; LENALIDOMIDE; OBINUTUZUMAB; PREDNISONE; RITUXIMAB; TOCILIZUMAB; VINCRISTINE SULFATE
    2023-506906-38-00 17 countries 2024 n=357 Orphan
    Ended
  • Celgene Corp. Commercial
    GOLCADOMIDE
    2024-519152-82-00 8 countries 2025 n=130 Orphan
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2023-505807-21-00 5 countries 2021 n=150
    Ended
  • Kite Pharma Inc. Commercial
    AXICABTAGENE CILOLEUCEL; BENDAMUSTINE HYDROCHLORIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN HYDROCHLORIDE; LENALIDOMIDE; PREDNISOLONE; RITUXIMAB; VINCRISTINE SULFATE
    2024-511594-30-00 4 countries 2023 n=142 Orphan
    Ended
  • Regeneron Pharmaceuticals Inc. Commercial
    ODRONEXTAMAB; RITUXIMAB
    2022-503092-28-00 8 countries 2024 n=234 Orphan
    Recruiting
  • LYSARC Academic
    DEXCHLORPHENIRAMINE MALEATE; FLUDEOXYGLUCOSE (18F); MOSUNETUZUMAB; OBINUTUZUMAB; RITUXIMAB
    2023-505436-35-00 6 countries 2024 n=694 Orphan
    Recruiting

Phase II

9 trials
  • AstraZeneca AB Commercial
    HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST CD3 AND CD19; SUROVATAMIG
    2023-505789-27-00 6 countries 2025 n=82
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    NEMTABRUTINIB; ZILOVERTAMAB VEDOTIN
    2022-501374-19-00 9 countries 2022 n=103
    Recruiting
  • Novartis Pharma AG Commercial
    IMP not specified
    2023-508127-13-00 7 countries 2019 n=41
    Ended
  • Aalborg University Hospital Academic
    IMP not specified
    2025-521205-41-00 1 country 2026 n=74
    Recruiting
  • Fondazione Italiana Linfomi Ets Academic
    MOSUNETUZUMAB; ZANUBRUTINIB
    2023-506049-52-00 1 country 2024 n=40
    Ended
  • Karolinska University Hospital Academic
    TAFASITAMAB
    2023-508196-36-00 5 countries 2025 n=270
    Recruiting
  • Rigshospitalet Academic
    CLIC-1901 CART; TOCILIZUMAB
    2024-515174-27-00 1 country 2022 n=15
    Recruiting
  • Universitaet Muenster Academic
    EPCORITAMAB; LONCASTUXIMAB TESIRINE
    2023-509861-19-00 1 country n=104 Orphan
    Not authorised
  • Universitaet Muenster Academic
    EPCORITAMAB; LONCASTUXIMAB TESIRINE
    2023-509861-19-01 1 country 2025 n=104 Orphan
    Recruiting

Phase I/II

1 trial
  • F. Hoffmann-La Roche AG Commercial
    LENALIDOMIDE; MOSUNETUZUMAB; TOCILIZUMAB
    2023-507236-20-00 2 countries 2020 n=117
    Ended

Phase IV

1 trial
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IBRUTINIB
    2023-507329-40-00 7 countries 2017 n=125
    Ended

Phase I

2 trials
  • Exscientia AI Limited Commercial
    IMP not specified
    2024-516869-36-00 5 countries 2025 n=101
    Recruiting
  • Miltenyi Biomedicine GmbH Commercial
    AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR EXPRESSING A CHIMERIC ANTIGEN RECEPTOR DIRECTED AGAINST CD19
    2024-513334-38-00 1 country 2018 n=49
    Ended

Phase I (Other)

2 trials
  • Pfizer Inc. Commercial
    IMP not specified
    2023-508371-36-00 1 country 2024 n=6
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2024-516907-18-00 1 country 2024 n=16
    Ended

Phase I (First in Human)

1 trial
  • Novartis Pharma AG Commercial
    RAPCABTAGENE AUTOLEUCEL
    2023-507062-34-00 5 countries 2020 n=142
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Pfizer Inc. Commercial 2 Phase I (Other) 0
Novartis Pharma AG Commercial 2 Phase II, Phase I (First in Human) 0
AbbVie Deutschland GmbH & Co. KG Commercial 2 Phase III, Phase IV 0
F. Hoffmann-La Roche AG Commercial 2 Phase III, Phase I/II 0
Universitaet Muenster Academic 2 Phase II 1
Exscientia AI Limited Commercial 1 Phase I 1
Miltenyi Biomedicine GmbH Commercial 1 Phase I 0
AstraZeneca AB Commercial 1 Phase II 1
Merck Sharp & Dohme LLC Commercial 1 Phase II 1
Celgene Corp. Commercial 1 Phase III 1
Kite Pharma Inc. Commercial 1 Phase III 0
Regeneron Pharmaceuticals Inc. Commercial 1 Phase III 1
Aalborg University Hospital Academic 1 Phase II 1
Fondazione Italiana Linfomi Ets Academic 1 Phase II 0
Karolinska University Hospital Academic 1 Phase II 1
Rigshospitalet Academic 1 Phase II 1
LYSARC Academic 1 Phase III 1
New trials by year
2019
1
2020
2
2021
1
2022
2
2023
1
2024
6
2025
5
2026
1
← All indication landscapes